Elevated Plasma Concentrations of Pigment Epithelium‐derived Factor in Type 2 Diabetic Patients is Reduced by Metformin Treatment in Association with Weight Loss

Zhijuan Ge,Pengzi Zhang,Yan Bi,Cuiliu Li,Huijie Yang,Dalong Zhu

DOI: https://doi.org/10.1111/1753-0407.12299

IF: 4.53

2015-01-01

Journal of Diabetes

Abstract:Pigment epithelium-derived factor (PEDF) was recently found to be closely associated with metabolic syndrome and insulin resistance. However, there is a lack of evidence quantitating PEDF levels in subjects with different glucose tolerance status and it is not known whether metformin treatment can affect PEDF concentrations. In this study, 517 Chinese subjects were categorized as having normal glucose tolerance (NGT), impaired glucose regulation (IGR), or type 2 diabetes mellitus (T2DM) using the guidelines of the International Diabetes Federation. In addition, 63 patients with newly diagnosed T2DM were treated for 24 weeks with metformin. Circulating PEDF concentrations and metabolic profiles were assessed. The study protocol was approved by the Ethics Committee of Drum Tower Hospital. Body mass index (BMI) classifications were in accordance with World Health Organization guidelines. Of the 517 participants (42.6% men, 57.4% women; mean [± SD] age 49.7 ± 14.5 years), 186 had NGT, 216 had IGR, and 169 had diabetes. Median serum PEDF concentrations were significantly higher in subjects with IGR (9.5 μg/mL; interquartile range [IQR] 7.6–11.4 μg/ mL) and T2DM (9.7 μg/mL; IQR 7.9–11.7 μg/mL), than in those with NGT (8.5 μg/mL; IQR 7.1–10.7 μg/mL; P = 0.010; Fig. 1a). For the metformin-treated group, PEDF concentrations were significantly lower after treatment in T2DM patients who lost weight (n = 47; from 9.2 [7.2–11.7] to 8.1 [6.2–9.9] μg/mL; P = 0.027), whereas there was no significant difference in PEDF concentrations before and after metformin treatment in the group of patients who did not lose weight on metformin treatment (n = 16; 9.1 [7.8–11.1] vs 10.6 [7.1–13.0] μg/mL, respectively; P > 0.05; Fig. 1b). Spearman correlation analysis demonstrated that PEDF concentrations were significantly correlated with risk factors for metabolic syndrome and visceral obesity (P < 0.001). In multiple stepwise regression, PEDF was associated with alanine aminotransferase (P < 0.001), triglycerides (P = 0.002) and diastolic blood pressure (P = 0.002) after adjustment for age and gender. Subjects in the second and third tertiles of PEDF concentrations (8.0–10.4 and 10.4–32.0 μg/mL, respectively) exhibited a higher prevalence of overweight or obesity than those in the first tertile (3.2–8.0 μg/mL; P < 0.001), and the prevalence of overweight or obesity was higher for those in the third tertile than in the second tertile. Furthermore, serum PEDF concentrations were significantly higher in men than in women (9.6 [7.9–11.9] vs 8.9 [7.4–10.8] μg/mL, respectively; P = 0.003) and this difference remained after adjusting for BMI, waist circumference, and the waist-to-hip ratio (P = 0.009; Fig. 1c). Estradiol concentrations were negatively associated with PEDF (r = −0.216, P = 0.013; Fig. 1d) and were independent determinants of PEDF in postmenopausal women. In conclusion, PEDF concentrations are significantly elevated in patients with glucose intolerance and could be reduced by metformin treatment in T2DM patients who lost weight while on metformin treatment. Some in vitro studies have suggested a link between estradiol and PEDF concentrations. To the best of our knowledge, the present study is the first to identify decreased estradiol as an independent risk factor for increased PEDF concentrations, which may contribute to the occurrence of T2DM in postmenopausal women.